1H NMR analysis and in vitro bioactivity of Leu27-bGRF(1-29)NH2 and its D-Ala2 and des-(Tyr1-Ala2)-analogs
- PMID: 1667740
1H NMR analysis and in vitro bioactivity of Leu27-bGRF(1-29)NH2 and its D-Ala2 and des-(Tyr1-Ala2)-analogs
Abstract
Relative growth hormone-releasing potencies of bovine growth hormone-releasing factor (bGRF) analogs bGRF(1-44)NH2 (I), Leu27-bGRF(1-29)NH2 (II) and D-Ala2, Leu27-bGRF(1-29)NH2 (III) in in vitro bovine anterior pituitary cell cultures were determined to be 100%, 48% and 77%, respectively. The potencies of II and III, although numerically different, were not statistically different. Leu27-bGRF(3-29)NH2 (IV) was approximately 10,000 times less potent than 1. 1H NMR studies of peptides II, III and IV in 35% d3-2,2,2-trifluorethanol (TFE)/65% phosphate buffer at pH 4 revealed very similar, highly helical secondary structures in the 8-29 region, with only subtle differences at the N-termini. This lack of correlation between secondary structure in solution and in vitro bioactivity suggests that either 1) the biological conformations induced at the GRF receptor for II and III vs. IV are different from those generated in TFE/buffer, 2) similar secondary structures may be necessary but not sufficient for the observed bioactivity or 3) residues 1 and 2 of analogs II and III are important contact residues crucial for effective GRF-receptor interaction.
Similar articles
-
In vitro metabolic degradation of a bovine growth hormone-releasing factor analog Leu27-bGRF(1-29)NH2 in bovine and porcine plasma. Correlation with plasma dipeptidylpeptidase activity.Drug Metab Dispos. 1989 Jul-Aug;17(4):393-7. Drug Metab Dispos. 1989. PMID: 2571478
-
Pegylated peptides. IV. Enhanced biological activity of site-directed pegylated GRF analogs.Int J Pept Protein Res. 1995 Sep-Oct;46(3-4):253-64. Int J Pept Protein Res. 1995. PMID: 8537179
-
Position 2 and position 2/Ala15-substituted analogs of bovine growth hormone-releasing factor (bGRF) with enhanced metabolic stability and improved in vivo bioactivity.J Med Chem. 1993 Apr 2;36(7):888-97. doi: 10.1021/jm00059a014. J Med Chem. 1993. PMID: 8464043
-
Effect of secondary structure on the rate of deamidation of several growth hormone releasing factor analogs.Int J Pept Protein Res. 1993 Dec;42(6):497-503. doi: 10.1111/j.1399-3011.1993.tb00356.x. Int J Pept Protein Res. 1993. PMID: 8307680
-
Growth hormone-releasing factor: structural modification or protection for more potent analogs.Comb Chem High Throughput Screen. 2006 Mar;9(3):171-4. doi: 10.2174/138620706776055511. Comb Chem High Throughput Screen. 2006. PMID: 16533149 Review.
Cited by
-
The mass spectrometry of helical unfolding in peptides.J Am Soc Mass Spectrom. 1994 May;5(5):425-33. doi: 10.1016/1044-0305(94)85058-5. J Am Soc Mass Spectrom. 1994. PMID: 24222597
-
Probing the helical content of growth hormone-releasing factor analogs using electrospray ionization mass spectrometry.J Am Soc Mass Spectrom. 1993 Aug;4(8):646-51. doi: 10.1016/1044-0305(93)85029-W. J Am Soc Mass Spectrom. 1993. PMID: 24227668
-
Inhibition of calmodulin-dependent myosin light-chain kinase by growth-hormone-releasing factor and vasoactive intestinal peptide.Biochem J. 1994 Jun 15;300 ( Pt 3)(Pt 3):901-5. doi: 10.1042/bj3000901. Biochem J. 1994. PMID: 8010976 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources